Cannvas MedTech (CSE:MTEC), a leader in digital cannabis education and a leading business technology company in the cannabis space, is pleased to announce the inception of its Cannvas Health Advocacy Team (CHAT) to delve deeper into health conditions and provide clarity on lesser-known medical ailments affecting large swaths of the population. Each CHAT module will focus on a particular illness, with a breakdown of its history, symptoms and potential treatments alongside patient and caregiver stories, doctor discussion guides and additional resources.
The first CHAT project, in partnership with Pancreatic Cancer Canada to mark National Pancreatic Cancer Awareness Month in November, is online at Cannvas.Me/PancreaticCancer with more to be announced shortly.
“The Cannvas Health Advocacy Team plays a crucial role on the Cannvas.Me platform, delivering a richer understanding of complicated ailments in simple terms anyone can understand, highlighting critical illnesses and conditions alongside potential alternative treatments and real-life patient and caregiver stories,” said Steve Loutskou, Chief Operating Officer, Global Markets at Cannvas MedTech. “It made sense to debut our first CHAT module to coincide with National Pancreatic Cancer Awareness Month to shed more light on a terrible disease with low survival rates and little public awareness that has personally affected the loved ones of several of our Cannvas employees, and we hope to continue educating our community about serious medical issues that could affect them or their loved ones.”
Made up of members of the Cannvas.Me Medical Advisory Board and Educational Advisory Panel, the Cannvas Health Advocacy Team aligns original educational Cannvas.Me content with expert medical advice from strategic partners in the healthcare, education, public safety and health advocacy sectors. With support from certified medical practitioners and sanctioned non-profit organizations, CHAT aims to break down an illness by laying out its history, cultural impact, symptoms and treatments in simple and accessible terms; provide supporting resources such as discussion guides for families and doctors; and share information on the potential benefits of cannabis as an alternative or supporting treatment where appropriate.
“Our goal with the Cannvas Health Advocacy Team is to give a voice to all those patients and caregivers navigating the challenges of unexpected and unfamiliar illnesses with little support, and provide them with another community from which to learn about their options and hear from others who have gone through similar experiences,” said Shawn Moniz, Chief Executive Officer at Cannvas MedTech. “By tapping into our internal team of health practitioners and certified educators, coupled with the resources provided by our partner organizations, CHAT provides free and unbiased educational content around medical conditions needing more clarity among everyday Canadians.”
By gathering and sharing user-submitted patient and caregiver stories pertaining to the illness profiled, the Cannvas Health Advocacy Team hopes to engage the Cannvas community to share their experiences, support systems and alternative or supporting therapies including but not limited to the use of cannabis. Working with healthcare practitioners and educators holding specializations in their fields strengthens the unbiased information available in CHAT modules to Cannvas.Me users and sheds more light on a litany of diseases with low public awareness.
Cannvas will also look to continue to form strategic partnerships with regional and national health-focused non-profit advocacy groups to strengthen its pool of resources for CHAT and the Cannvas.Me platform.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.
For further information: www.cannvasmedtech.com; Media Inquiries: email@example.com; Investor Relations, firstname.lastname@example.org, 1-800-489-0116
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact email@example.com, or